Search

Displaying results 9091 - 9100 of 10000 in total
  1. Drug

    Lerdelimumab

    go.drugbank.com/drugs/DB06557
    Experimental

  2. Drug

    Triphendiol

    go.drugbank.com/drugs/DB06588
    Experimental

  3. Drug

    MC-1

    go.drugbank.com/drugs/DB05315
    Experimental

    Medicure's MC-1 drug is a cardio-protectant, designed to reduce the damage to the heart when arteries are blocked and when they are subsequently reopened after bypass surgery.

  4. Drug

    Psilocybin

    go.drugbank.com/drugs/DB11664
    Investigational

    In November, 2019, it was granted Breakthrough Therapy status by the FDA.

  5. Drug

    Aceneuramic acid

    go.drugbank.com/drugs/DB11797
    Investigational

    Aceneuramic acid has been used in trials studying the treatment of Distal Myopathy, Nonaka Type, Hereditary Inclusion Body Myopathy, and Distal Myopathy With Rimmed Vacuoles.

  6. Drug

    PZ-128

    go.drugbank.com/drugs/DB11839
    Investigational

    PZ-128 has been used in trials studying the prevention and treatment of Heart Diseases, Coronary Disease, Arteriosclerosis, Vascular Diseases, and Myocardial Ischemia, among others.

  7. Drug

    ATX-F8-117

    go.drugbank.com/drugs/DB17712
    Experimental

    ATX-F8-117 is an investigational peptide derived from Factor VIII. Developed by Apitope, it is being investigated for the treatment of hemophilia A.[L46163]

  8. Drug

    BHV-5000

    go.drugbank.com/drugs/DB17817
    Experimental

    BHV-5000 is an orally bioavailable, low-trapping, potent N-methyl-D-aspartate (NMDA) receptor antagonist. The active metabolite of BHV-5000 is [lanicemine].[L46446]

  9. Drug

    inBreath airway transplant system

    go.drugbank.com/drugs/DB18692
    Experimental

    inBreath airway transplant system composes of a scaffold seeded with autologous bone marrow cells and incubated in the bioreactor for two days prior to implant.

  10. Drug

    Coagulation factor XIa

    go.drugbank.com/drugs/DB15420
    Investigational

    Coagulation factor XIa is under investigation in clinical trial NCT01701947 (HEMOLEVEN® Expanded Access Program Prevention of Surgical/Postpartum Hemorrhage Severe Inherited Factor XI Deficiency).